The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsMolecular and therapeutic potential and toxicity of valproic acidSynergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stressPCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cellsClinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitorHistone acetylation: novel target for the treatment of acute lymphoblastic leukemiaTargeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implicationsHistone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell ViabilityHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyOvercoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanateTrichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cellsIntegrating genomics and proteomics data to predict drug effects using binary linear programmingThe histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines.Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinaseA phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancerRole of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathwayInhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ ExpressionInduction of sirtuin-1 signaling by resveratrol induces human chondrosarcoma cell apoptosis and exhibits antitumor activityBortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Chromatin Regulates Genome Targeting with Cisplatin.Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.Interpreting clinical assays for histone deacetylase inhibitors.In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cellsEpigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat.Augmenting antitumor immune responses with epigenetic modifying agents.HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.
P2860
Q21198868-FA6B738C-F539-4642-9A69-9EB82DC4CA84Q21296867-A92EDC44-9F54-4DAB-B53D-2D7BFD51E2E0Q23918915-42259091-2B25-419D-A2A4-D5CD24444EE4Q24654958-0A5D0636-A6F4-494B-B0B3-961E12F4EA60Q26747768-0F8F882C-BE0F-41DE-97F7-DDD0E6A82D30Q26778780-D3A6E01D-0181-4582-8D00-2C09B4763C29Q26853394-0D280E3F-5C29-4CDF-900F-3C7563C75997Q27679266-CBA07D00-A60A-4C6D-B062-72A58C1EC3FCQ28082536-A0AC9BAC-1CE1-4E1F-8D30-12DECE950ABFQ28383320-25DCE70D-2581-46E8-BDED-3551C0188D21Q28540870-679C0936-6CFD-483D-AFAF-CD3F88E2B9D2Q28540932-F30D8922-DD4E-4698-9FA7-9B6AA2AE617FQ30368366-1D58F650-B032-442E-A13A-8FD311F18961Q33521840-7F4A2640-7B03-45B2-852E-14A7A8822FBFQ33619776-FFA68933-F778-4DDA-9F5B-022687F10559Q33651762-6E46F5D6-A0E6-4A7F-B5CE-A64225BDB8B6Q33697130-0B0AC2A7-0E1D-4526-8254-650B2A6704BDQ33705588-672041F4-CA4E-4E3C-B874-DBCC5098230BQ33741142-C209A2FF-6157-4EE6-9890-046694A3654EQ33744417-F1FBB767-B7F3-4B59-9B74-DA792C97A35AQ33755131-6757DEE1-EDF9-44CE-B2C3-41752AF27F88Q33784452-8EC0A030-9DB9-48ED-939B-49B1210E2D35Q33798624-F945DC78-E174-41DD-8158-340538EE9333Q33829390-5312023E-C752-4DB1-BF6E-F75456BF1C88Q33845705-740AC137-0B8B-4512-93D2-CE974C1F6E0EQ33860585-4A089B83-B8A9-49FF-9946-09C6A7A62E5BQ33863049-6939568B-B5BB-46B1-8105-BB92CB0B0CCEQ33937865-DC89EB0E-FC00-4A07-AE1D-693045390BABQ33983255-D4F4564C-AA9D-42EA-B2D0-D8E5A4B27609Q33989217-01731544-2F12-47EC-B5A1-146D5833FA5DQ34171631-F2361AC2-FE2B-472F-8943-CA7796A2DE76Q34224278-D812FA78-4EB8-4EA0-A9C3-0516AB2A1BFDQ34240470-981FF44F-B81D-43CE-86AD-559A984AC377Q34440758-302C1BFD-152A-47D7-937D-DF285F908FB7Q34988013-64554C86-040E-49A1-BD27-5D0089421D5CQ35003657-FFE3928D-7132-48FE-AC76-57CC900645BCQ35007061-5FD7DA38-ED6D-4B9E-954E-04DE74F25456Q35014402-C7B3E5C0-5B90-465E-B627-D009F3340666Q35048054-E19CF3C9-D08C-4DF8-AFF2-10CDE8C517B6Q35070712-1425E66E-BD36-48D6-8EA5-97094941BBE6
P2860
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The histone deacetylase inhibi ...... d induction of p21CIP1/WAF1 1.
@en
The histone deacetylase inhibi ...... d induction of p21CIP1/WAF1 1.
@nl
type
label
The histone deacetylase inhibi ...... d induction of p21CIP1/WAF1 1.
@en
The histone deacetylase inhibi ...... d induction of p21CIP1/WAF1 1.
@nl
prefLabel
The histone deacetylase inhibi ...... d induction of p21CIP1/WAF1 1.
@en
The histone deacetylase inhibi ...... d induction of p21CIP1/WAF1 1.
@nl
P2093
P1433
P1476
The histone deacetylase inhibi ...... nd induction of p21CIP1/WAF1 1
@en
P2093
Jorge A Almenara
Roberto R Rosato
Steven Grant
P304
P407
P577
2003-07-01T00:00:00Z